StockData
Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc. (CRL) stock

CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30225% above fair value
$332.16−3.36 (-1.00%)

Close on Nov 17, 2026Market cap $15.86BP/E –Yield –

Charles River Laboratories International total assets

Total assets on the balance sheet at the end of each period.

Charles River Laboratories International's total assets was $7.53B at Jun 27, 2026. For fiscal 2025 it was $7.14B, down 5.2% from the year before. Over ten years it grew 13.2% a year on average. The highest annual figure on record is $8.20B in fiscal 2023.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 27, 2025$7.14B-5.2%
FY2024Dec 28, 2024$7.53B-8.1%
FY2023Dec 30, 2023$8.20B+7.8%
FY2022Dec 31, 2022$7.60B+8.2%
FY2021Dec 25, 2021$7.02B+27.9%
FY2020Dec 26, 2020$5.49B+17.0%
FY2019Dec 28, 2019$4.69B+21.7%
FY2018Dec 29, 2018$3.86B+31.6%
FY2017Dec 30, 2017$2.93B+8.0%
FY2016Dec 31, 2016$2.71B+31.1%
FY2015Dec 26, 2015$2.07B+10.6%
FY2014Dec 27, 2014$1.87B+14.6%
FY2013Dec 28, 2013$1.63B+2.9%
FY2012Dec 29, 2012$1.59B+1.8%
FY2011Dec 31, 2011$1.56B-10.1%
FY2010Dec 25, 2010$1.73B-21.4%
FY2009Dec 26, 2009$2.20B–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 27, 2026$7.53B-0.4%
Q1 FY2026Mar 28, 2026$7.73B+2.0%
Q4 FY2025Dec 27, 2025$7.14B-5.2%
Q3 FY2025Sep 27, 2025$7.51B-6.1%
Q2 FY2025Jun 28, 2025$7.56B-4.9%
Q1 FY2025Mar 29, 2025$7.58B-7.0%
Q4 FY2024Dec 28, 2024$7.53B-8.1%
Q3 FY2024Sep 28, 2024$8.00B+5.2%
Q2 FY2024Jun 29, 2024$7.95B+2.3%
Q1 FY2024Mar 30, 2024$8.15B+5.9%
Q4 FY2023Dec 30, 2023$8.20B+7.8%
Q3 FY2023Sep 30, 2023$7.61B+3.0%
Q2 FY2023Jul 1, 2023$7.77B+3.2%
Q1 FY2023Apr 1, 2023$7.70B+8.8%
Q4 FY2022Dec 31, 2022$7.60B+8.2%
Q3 FY2022Sep 24, 2022$7.38B+4.6%
Q2 FY2022Jun 25, 2022$7.53B+12.0%
Q1 FY2022Mar 26, 2022$7.08B+21.8%
Q4 FY2021Dec 25, 2021$7.02B+27.9%
Q3 FY2021Sep 25, 2021$7.06B+35.4%
Q2 FY2021Jun 26, 2021$6.72B+28.2%
Q1 FY2021Mar 27, 2021$5.81B+11.7%
Q4 FY2020Dec 26, 2020$5.49B+17.0%
Q3 FY2020Sep 26, 2020$5.21B+13.8%
Q2 FY2020Jun 27, 2020$5.24B+13.3%
Q1 FY2020Mar 28, 2020$5.20B+32.5%
Q4 FY2019Dec 28, 2019$4.69B+21.7%
Q3 FY2019Sep 28, 2019$4.58B+20.7%
Q2 FY2019Jun 29, 2019$4.63B+19.6%
Q1 FY2019Mar 30, 2019$3.93B+30.8%
Q4 FY2018Dec 29, 2018$3.86B+31.6%
Q3 FY2018Sep 29, 2018$3.80B+32.5%
Q2 FY2018Jun 30, 2018$3.87B+39.4%
Q1 FY2018Mar 31, 2018$3.00B+11.3%
Q4 FY2017Dec 30, 2017$2.93B+8.0%
Q3 FY2017Sep 30, 2017$2.87B+6.5%
Q2 FY2017Jul 1, 2017$2.77B–
Q1 FY2017Apr 1, 2017$2.70B–
Q4 FY2016Dec 31, 2016$2.71B–
Q3 FY2016Sep 24, 2016$2.69B–

More Charles River Laboratories International figures

See a number that looks wrong?